Join
Live feed
·
PRReleasevia Quantisnow
Gilead Sciences Inc. logo
Arcus Biosciences Inc. logo

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

ByQuantisnow·Wall Street's wire, on your screen.
GILD· Gilead Sciences Inc.RCUS· Arcus Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GILD (Gilead Sciences Inc.), RCUS (Arcus Biosciences Inc.) and more on Quantisnow.